Abstract:The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell types within the human body. This receptor specifically interacts with GLP-1, a key hormone that plays an integral role in regulating blood glucose levels, lipid metabolism, and several other crucial biological functions. In recent years, GLP-1 medications have become a focal point in the medical community due to their innovative treatment mechanisms, significant therapeutic efficacy, and broad development prospects. This article thoroughly traces the developmental milestones of GLP-1 drugs, from their initial discovery to their clinical application, detailing the evolution of diverse GLP-1 medications along with their distinct pharmacological properties. Additionally, this paper explores the potential applications of GLP-1 receptor agonists (GLP-1RAs) in fields such as neuroprotection, anti-infection measures, the reduction of various types of inflammation, and the enhancement of cardiovascular function. It provides an in-depth assessment of the effectiveness of GLP-1RAs across multiple body systems-including the nervous, cardiovascular, musculoskeletal, and digestive systems. This includes integrating the latest clinical trial data and delving into potential signaling pathways and pharmacological mechanisms. The primary goal of this article is to emphasize the extensive benefits of using GLP-1RAs in treating a broad spectrum of diseases, such as obesity, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), neurodegenerative diseases, musculoskeletal inflammation, and various forms of cancer. The ongoing development of new indications for GLP-1 drugs offers promising prospects for further expanding therapeutic interventions, showcasing their significant potential in the medical field.

Class B1 GPCRs: Insights into Multi-Receptor Pharmacology for the Treatment of Metabolic Disease

Insights into the structure and activation mechanism of some class B1 GPCR family members

Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation.

GPCRs involved in metabolic diseases: pharmacotherapeutic development updates

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

Molecular features of the ligand-free GLP-1R, GCGR and GIPR in complex with G s proteins

Conserved class B GPCR activation by a biased intracellular agonist

A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor

Isoquinoline small molecule ligands are agonists and probe-dependent allosteric modulators of the glucagon subfamily of GPCRs

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

Non‐peptide agonists and positive allosteric modulators of glucagon‐like peptide‐1 receptors: Alternative approaches for treatment of Type 2 diabetes

Structural perspective of class B1 GPCR signaling

Phase-plate Cryo-Em Structure of a Class B GPCR–G-protein Complex

Structural Analysis of the Dual Agonism at GLP-1R and GCGR

Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors

Selective Polypeptide Ligand Binding to the Extracellular Surface of the Transmembrane Domains of the Class B GPCRs GLP-1R and GCGR

The G Protein-First Mechanism for Activation of the Class B Glucagon-like Peptide 1 Receptor Coupled to N-Terminal Domain-Mediated Conformational Progression

The Nature of Functional Features of Different Classes of G-Protein-Coupled Receptors

G Protein-Coupled Receptors in Energy Homeostasis

G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasis

Progress on the development of Class A GPCR‐biased ligands